Navellier & Associates Inc cut its stake in shares of Cambrex Corporation (NYSE:CBM) by 14.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,877 shares of the biotechnology company’s stock after selling 2,017 shares during the period. Navellier & Associates Inc’s holdings in Cambrex Corporation were worth $710,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cambrex Corporation during the second quarter worth $238,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Cambrex Corporation during the second quarter worth $421,000. The Manufacturers Life Insurance Company grew its stake in shares of Cambrex Corporation by 1.3% during the second quarter. The Manufacturers Life Insurance Company now owns 25,099 shares of the biotechnology company’s stock worth $1,500,000 after purchasing an additional 321 shares during the period. State Street Corp grew its stake in shares of Cambrex Corporation by 5.1% during the second quarter. State Street Corp now owns 779,820 shares of the biotechnology company’s stock worth $46,600,000 after purchasing an additional 37,669 shares during the period. Finally, Flinton Capital Management LLC grew its stake in shares of Cambrex Corporation by 90.9% during the second quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 1,700 shares during the period.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the sale, the chief executive officer now directly owns 87,328 shares in the company, valued at approximately $4,799,546.88. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $51.53, for a total value of $618,360.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at $4,912,251.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,000 shares of company stock valued at $1,574,880. Company insiders own 2.48% of the company’s stock.
Cambrex Corporation (NYSE CBM) traded up 1.64% on Wednesday, reaching $52.65. The company’s stock had a trading volume of 54,244 shares. The company has a market cap of $1.72 billion, a P/E ratio of 19.18 and a beta of 2.28. The stock’s 50 day moving average price is $53.21 and its 200 day moving average price is $55.53. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The firm had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same period last year, the business posted $0.68 EPS. The business’s revenue was up 13.4% compared to the same quarter last year. Equities research analysts forecast that Cambrex Corporation will post $3.08 earnings per share for the current year.
Several research analysts have weighed in on the company. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Finally, Zacks Investment Research lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $65.67.
ILLEGAL ACTIVITY NOTICE: “Navellier & Associates Inc Has $710,000 Position in Cambrex Corporation (CBM)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/10/18/navellier-associates-inc-has-710000-position-in-cambrex-corporation-cbm.html.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.